Lung cancers that harbor somatic activating mutations in the gene for EGFR depend on mutant EGFR for their proliferation and survival; therefore, lung cancer patients with EGFR mutation often dramatically respond to orally available EGFR-TKIs. This evidence concerns the gene EGFR and lung cancer.